buprenorphine naloxone
Adjunctive therapy • Brands: Suboxone
Last reviewed: 2026-02-12
General information
- Class: Adjunctive therapy
- Common US brands: Suboxone
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Combination of buprenorphine (partial μ-opioid receptor agonist) and naloxone (opioid antagonist) used for treatment of opioid use disorder. Naloxone has low bioavailability sublingually but deters injection misuse (label/guideline).
Metabolism & Half‑life
- Metabolism: CYP3A4 (buprenorphine), UGT1A1/UGT2B7 (buprenorphine glucuronidation)
- Half‑life: Single-dose range 24–42 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- SUBOXONE (buprenorphine hydrochloride and naloxone hydrochloride) sublingual film prescribing information — DailyMed (2026)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update — Journal of Addiction Medicine (2020)
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)
- Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence — Cochrane Database of Systematic Reviews (2014)